Search Results
OlympiA: adjuvant olaparib in gBRCAm, HER2-negative, high-risk, early breast cancer
Perspectives on the OlympiA study of adjuvant olaparib in early breast cancer | Nadine Tung
OlympiA: adjuvant olaparib following chemo significantly improves IDFS
Breast Cancer Breakthrough - Prof Andrew Tutt on the OlympiA trial
PARP Inhibitor Staves Off Recurrence in Early BRCA-Mutant Breast Cancer - Medpage Today
The Promise of Olaparib for the Treatment of HER2-Negative Breast Cancer
Dr. Tung Discusses the Role of Olaparib in Breast Cancer
Exploring the use of olaparib in advanced breast cancer
Dr. Robson on the Toxicity Profile of Olaparib in Breast Cancer
Adjuvant Endocrine Therapy for high-risk breast cancer
Dr. Litton on Activity of Talazoparib in Advanced BRCA1/2+ Breast Cancer
Breast cancer trial updates at ESMO 2021
